Autres langues Galderma Group AG

Actions

GALD

CH1335392721

Produits cosmétiques

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:27 20/06/2025			Varia. 5j.	Varia. 1 janv.
112,10 ^CHF	0,00%		+0,72%	+11,39%

18/06	Galderma : de nouveaux résultats intermédiaires confirment l’efficacité à long terme de Nemluvio dans le prurigo nodulaire modéré à sévère	CI
18/06	Should I Stay or Should I go ?

Autres langues

Galderma Announces Data from New Interim Analysis of Study Investigating the Long-Term Safety and Efficacy of Nemluvio in Moderate-To-Severe Prurigo Nodularis	18/06
Aktien Schweiz Vorbörse: Nahost-Krise hat Märkte vor Fed im Griff	18/06
Morning Briefing - Markt Schweiz	18/06
Galderma präsentiert neue Langzeitdaten zu Hoffnungsträger Nemluvio	18/06
Galderma Group AG - New Data Demonstrate Nemluvio®'S (Nemolizumab) Favorable Safety Profile	18/06
Galderma Publishes New Data On Nemluvio's Safety Profile	18/06
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years	18/06
Swiss stocks - Factors to watch on June 18	18/06
Galderma apre la nuova sede statunitense a Miami	17/06
Galderma eröffnet neuen US-Hauptsitz in Miami und ernennt US-Länderchefin	17/06
Galderma Establishes New U.S. Headquarters In Miami	17/06
Galderma Establishes New U.S. Headquarters in Miami and Strengthens Regional Leadership	17/06
Galderma?S Nemluvio® (Nemolizumab) Receives National Institute for Health and Care Excellence Recommendation for Moderate-To-Severe Atopic Dermatitis in England and Wales	12/06
Galderma's Atopic Dermatitis Drug Gets Backing for Routine NHS Funding	12/06
Galderma erhält für Nemolizumab Empfehlung zur Kostenübernahme	12/06
Galderma’s Nemluvio® (nemolizumab) Receives National Institute for Health and Care Excellence (NICE) Recommendation for Moderate-to-severe Atopic Dermatitis in England and Wales	12/06
Borsa svizzera: chiude in rialzo, SMI +0,39%	06/06
Galderma stellt neue Langzeitdaten zu Hoffnungsträger Nemluvio vor	06/06
Galderma Announces Two-Year Data from A New Interim Analysis of A Long-Term Extension Study Investigating the Safety and Efficacy of Nemluvio in Moderate-To-Severe Atopic Dermatitis	06/06
Galderma Says Long-Term Data On Nemluvio (Nemolizumab) Demonstrate Its Favorable Safety Profile	06/06
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years	06/06
Swiss stocks - Factors to watch on June 6	06/06
EQT Wraps Up CHF1.86 Billion Sale of Galderma Shares	03/06
EQT Completes Sale Of Shares In Galderma	03/06
EQT completes sale of shares in Galderma Group AG	03/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Galderma, une super cachette

Le 03 février 2025 à 12:17